Change of Adviser

 

TIDMMEDG 
 
RNS Number : 9768L 
Medgenics Inc 
17 May 2010 
 
For release: 17 May 2010 
 
                                Medgenics, Inc. 
                         ("Medgenics" or the "Company") 
 
                   Appointment of Nomura-Code as Joint-Broker 
Medgenics (LSE: MEDG, MEDU), the company that is developing a novel approach to 
the manufacture and delivery of therapeutic proteins continuously in patients 
using their own tissue, is proud to announce today the appointment of Nomura 
Code Securities as joint-broker to the Company with SVS Securities plc with 
immediate effect. 
Commenting on the new appointment Dr. Andrew Pearlman, CEO of Medgenics said: 
"We are delighted by this new appointment and believe that the combination of 
Nomura Code Securities, with acknowledged expertise in the life sciences space 
and its reputation amongst institutional investors, and SVS Securities plc, with 
its small cap investor expertise, greatly strengthens Medgenics broking team to 
support the Company going forward" 
For further information, please contact: 
Andrew Pearlman                                               + 972 4 902 8900 
CEO, Medgenics, Inc 
 
Mike Wort / Anna Dunphy                                   + 44 207 861 3838 
De Facto Communications 
 
Jonathan Senior                                                 [phone] 
Nomura Code 
 
Ian Callaway / Alex Mattey                                 [phone] 
SVS Securities 
 
James Pinner / Derek Crowhurst                         [phone] 
Religare Capital Markets (Nomad) 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 APPAIMITMBTBBLM